- Clearmind Medicine Granted Patent Approval in Hong Kong for its Binge Behaviors Treatment
- Clearmind Medicine Secured Exclusive Global Rights to Innovative Psychedelic Compounds for PTSD Treatment
- Clearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based Drink
- Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product
- Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment
- Clearmind Applies to Cease Being a Reporting Issuer in Canada
- Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders
- Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders
- Clearmind Medicine CEO Issues Letter to Shareholders
- Clearmind Medicine Announces International Patent Application for Preventing and Treating Depression
More ▼
Key statistics
As of last trade, Clearmind Medicine Inc (CMND:NAQ) traded at 1.55, 68.41% above the 52 week low of 0.9205 set on Jan 23, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.57 |
---|---|
High | 1.60 |
Low | 1.51 |
Bid | 1.55 |
Offer | 1.56 |
Previous close | 1.52 |
Average volume | 10.08m |
---|---|
Shares outstanding | 3.31m |
Free float | 3.31m |
P/E (TTM) | -- |
Market cap | 5.03m USD |
EPS (TTM) | -14.57 USD |
Data delayed at least 15 minutes, as of Jul 05 2024 16:13 BST.
More ▼